A Phase 1 study to look at RP-6306 in combination with FOLFIRI as a treatment for Advanced Solid Tumours

2024-511927-32-00 Protocol RP-6306-03 Human pharmacology (Phase I) - First administration to humans Ended

End 12 Feb 2025 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol RP-6306-03

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 106
Countries 1
Sites 4

Advanced solid tumours

Key facts

Sponsor
Repare Therapeutics USA Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
completed 12 Feb 2025
Decision date (initial)
2024-04-24
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-511927-32-00
EudraCT number
2021-006582-38
ClinicalTrials.gov
NCT05147350

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumours

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Repare Therapeutics USA Inc.

Sponsor organisation
Repare Therapeutics USA Inc.
Address
101 Main Street Suite 1650
City
Cambridge
Postcode
02142-1519
Country
United States

Scientific contact point

Organisation
Repare Therapeutics USA Inc.
Contact name
Nathan Hawkey, MD, MBA

Public contact point

Organisation
Repare Therapeutics USA Inc.
Contact name
clinical Development

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 26 4
Rest of world
Canada, United States, United Kingdom
80

Investigational sites

Spain

4 sites · Ended
Hospital Universitari Vall D Hebron
Medical Oncology Department, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Quironsalud Barcelona
Institute of Oncology Barcelona, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
START - Madrid -FJD, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario Hm Sanchinarro
Centro Integral Oncológico Clara Campal (CIOCC), Calle Ona 10, 28050, Madrid

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-15 Spain Acceptable
2024-04-24
2024-04-24
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-11 Spain Acceptable
2024-09-09
2024-09-09